Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens
Evaluation of Intravenous Gamma Globulin (IVIG) As an Agent to Lower Allosensitization and Improve Allograft Survival in Highly-Sensitized Adult End-Stage Renal Disease (ESRD) Patients (IG02)
Status: Enrolling
Updated:  1/10/2017
Ann Limberger
mi
from
Rockville, MD
An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens
Evaluation of Intravenous Gamma Globulin (IVIG) As an Agent to Lower Allosensitization and Improve Allograft Survival in Highly-Sensitized Adult End-Stage Renal Disease (ESRD) Patients (IG02)
Status: Enrolling
Updated: 1/10/2017
Ann Limberger
mi
from
Rockville, MD
Click here to add this to my saved trials
A Study To Test An Anti-Rejection Therapy After Kidney Transplantation
Controlled Trial of Induction Therapy in Renal Transplantation
Status: Enrolling
Updated:  1/10/2017
Ilene Blechman-Krom
mi
from
Rockville, MD
A Study To Test An Anti-Rejection Therapy After Kidney Transplantation
Controlled Trial of Induction Therapy in Renal Transplantation
Status: Enrolling
Updated: 1/10/2017
Ilene Blechman-Krom
mi
from
Rockville, MD
Click here to add this to my saved trials
Omega-3 Fatty Acids That Affect the Immune System in Kidney Transplant Patients
A Randomized Trial of Immunomodulating Diets With Arginine and Omega-3 Fatty Acids in Renal Transplant Recipients
Status: Enrolling
Updated:  1/10/2017
MedStar Washington Hospital Center
mi
from
Washington,
Omega-3 Fatty Acids That Affect the Immune System in Kidney Transplant Patients
A Randomized Trial of Immunomodulating Diets With Arginine and Omega-3 Fatty Acids in Renal Transplant Recipients
Status: Enrolling
Updated: 1/10/2017
MedStar Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
Omega-3 Fatty Acids That Affect the Immune System in Kidney Transplant Patients
A Randomized Trial of Immunomodulating Diets With Arginine and Omega-3 Fatty Acids in Renal Transplant Recipients
Status: Enrolling
Updated:  1/10/2017
University of Maryland School of Medicine
mi
from
Baltimore, MD
Omega-3 Fatty Acids That Affect the Immune System in Kidney Transplant Patients
A Randomized Trial of Immunomodulating Diets With Arginine and Omega-3 Fatty Acids in Renal Transplant Recipients
Status: Enrolling
Updated: 1/10/2017
University of Maryland School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
Omega-3 Fatty Acids That Affect the Immune System in Kidney Transplant Patients
A Randomized Trial of Immunomodulating Diets With Arginine and Omega-3 Fatty Acids in Renal Transplant Recipients
Status: Enrolling
Updated:  1/10/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Omega-3 Fatty Acids That Affect the Immune System in Kidney Transplant Patients
A Randomized Trial of Immunomodulating Diets With Arginine and Omega-3 Fatty Acids in Renal Transplant Recipients
Status: Enrolling
Updated: 1/10/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Omega-3 Fatty Acids That Affect the Immune System in Kidney Transplant Patients
A Randomized Trial of Immunomodulating Diets With Arginine and Omega-3 Fatty Acids in Renal Transplant Recipients
Status: Enrolling
Updated:  1/10/2017
University of Cincinnati College of Medicine
mi
from
Cincinnati, OH
Omega-3 Fatty Acids That Affect the Immune System in Kidney Transplant Patients
A Randomized Trial of Immunomodulating Diets With Arginine and Omega-3 Fatty Acids in Renal Transplant Recipients
Status: Enrolling
Updated: 1/10/2017
University of Cincinnati College of Medicine
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated:  1/10/2017
Children's Hospital of Alabama
mi
from
Birmingham, AL
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated: 1/10/2017
Children's Hospital of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated:  1/10/2017
Banner Good Samaritan Regional Medical Center
mi
from
Phoenix, AZ
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated: 1/10/2017
Banner Good Samaritan Regional Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated:  1/10/2017
UCLA Medical Center
mi
from
Los Angeles, CA
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated: 1/10/2017
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated:  1/10/2017
California Pacific Medical Center
mi
from
San Francisco, CA
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated: 1/10/2017
California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated:  1/10/2017
University of San Francisco
mi
from
San Francisco, CA
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated: 1/10/2017
University of San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated:  1/10/2017
MedStar Washington Hospital Center
mi
from
Washington,
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated: 1/10/2017
MedStar Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated:  1/10/2017
University of Miami
mi
from
Miami, FL
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated: 1/10/2017
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated:  1/10/2017
Emory University Hospital
mi
from
Atlanta, GA
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated: 1/10/2017
Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated:  1/10/2017
Indiana University Medical Center
mi
from
Indianapolis, IN
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated: 1/10/2017
Indiana University Medical Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated:  1/10/2017
University of Massachusetts Medical Center
mi
from
Worcester, MA
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated: 1/10/2017
University of Massachusetts Medical Center
mi
from
Worcester, MA
Click here to add this to my saved trials
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated:  1/10/2017
University of Michigan Hospitals
mi
from
Ann Arbor, MI
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated: 1/10/2017
University of Michigan Hospitals
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated:  1/10/2017
University of Cincinnati
mi
from
Cincinnati, OH
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated: 1/10/2017
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated:  1/10/2017
Rhode Island Hospital
mi
from
Providence, RI
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated: 1/10/2017
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated:  1/10/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated: 1/10/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated:  1/10/2017
University of Texas Medical Branch
mi
from
Galveston, TX
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated: 1/10/2017
University of Texas Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated:  1/10/2017
Swedish Medical Center
mi
from
Seattle, WA
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Status: Enrolling
Updated: 1/10/2017
Swedish Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Switching From One Type of Anti-rejection Drug (Tacrolimus or Cyclosporine) to Another (Sirolimus) Approximately 90-180 Days After Liver Transplantation
Sirolimus Switching From Calcinurin Inhibitors (CNI) 90 - 180 Days After Liver Transplantation
Status: Enrolling
Updated:  1/11/2017
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Switching From One Type of Anti-rejection Drug (Tacrolimus or Cyclosporine) to Another (Sirolimus) Approximately 90-180 Days After Liver Transplantation
Sirolimus Switching From Calcinurin Inhibitors (CNI) 90 - 180 Days After Liver Transplantation
Status: Enrolling
Updated: 1/11/2017
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study
Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study
Status: Enrolling
Updated:  1/11/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study
Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study
Status: Enrolling
Updated: 1/11/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study
Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study
Status: Enrolling
Updated:  1/11/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study
Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study
Status: Enrolling
Updated: 1/11/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study
Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study
Status: Enrolling
Updated:  1/11/2017
The Mayo Clinic
mi
from
Rochester, MN
Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study
Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study
Status: Enrolling
Updated: 1/11/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
University of Alabama at Birmingham (UAB)
mi
from
Birmingham, AL
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
University of Alabama at Birmingham (UAB)
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Chase Medcare
mi
from
Huntsville, AL
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Chase Medcare
mi
from
Huntsville, AL
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Choice Medicine
mi
from
Toney, AL
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Choice Medicine
mi
from
Toney, AL
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Akdhc Medical Research Services, Llc
mi
from
Peoria, AZ
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Akdhc Medical Research Services, Llc
mi
from
Peoria, AZ
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
AKDHC Medical Research Services, LLC
mi
from
Phoenix, AZ
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
AKDHC Medical Research Services, LLC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
AKDHC Medical Research Services, LLC
mi
from
Phoenix, AZ
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
AKDHC Medical Research Services, LLC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Akdhc Medical Research Services, Llc
mi
from
Prescott, AZ
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Akdhc Medical Research Services, Llc
mi
from
Prescott, AZ
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Robert J. Bloomberg, Md, Pc
mi
from
Tempe, AZ
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Robert J. Bloomberg, Md, Pc
mi
from
Tempe, AZ
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
AKDHC East Office
mi
from
Tucson, AZ
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
AKDHC East Office
mi
from
Tucson, AZ
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Clinical Research Connections, LLC
mi
from
Harrisburg, AR
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Clinical Research Connections, LLC
mi
from
Harrisburg, AR
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
North America Research Institute
mi
from
Azusa, CA
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
North America Research Institute
mi
from
Azusa, CA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
California Institute of Renal Research
mi
from
Chula Vista, CA
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
California Institute of Renal Research
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
California Institute of Renal Research Inc.
mi
from
El Centro, CA
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
California Institute of Renal Research Inc.
mi
from
El Centro, CA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Renal Consultants Medical Group Granada Hills
mi
from
Granada Hills, CA
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Renal Consultants Medical Group Granada Hills
mi
from
Granada Hills, CA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Torrance Clinical Research
mi
from
Lomita, CA
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Torrance Clinical Research
mi
from
Lomita, CA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Academic Medical Research Institute
mi
from
Los Angeles, CA
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Academic Medical Research Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
IMD Medical Group
mi
from
Los Angeles, CA
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
IMD Medical Group
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Kidney Research Center
mi
from
Lynwood, CA
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Kidney Research Center
mi
from
Lynwood, CA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Apex Research of Riverside
mi
from
Riverside, CA
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Apex Research of Riverside
mi
from
Riverside, CA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
San Francisco General Hospital
mi
from
San Francisco, CA
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
San Francisco General Hospital
mi
from
San Francisco, CA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Clearview Medical Research LLC
mi
from
Santa Clarita, CA
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Clearview Medical Research LLC
mi
from
Santa Clarita, CA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
American Institute of Research
mi
from
Whittier, CA
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
American Institute of Research
mi
from
Whittier, CA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Omega Research Consultants LLC
mi
from
Debary, FL
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Omega Research Consultants LLC
mi
from
Debary, FL
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Creekside Medical Research
mi
from
Deland, FL
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Creekside Medical Research
mi
from
Deland, FL
Click here to add this to my saved trials